|
|
|
Insider
Information: |
Friedman Paul A |
Relationship: |
Director |
City: |
Palo Lato |
State: |
CA |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
7 |
|
Direct
Shares |
964,465 |
|
Indirect Shares
|
670,540 |
|
|
Direct
Value |
$56,616,844 |
|
|
Indirect Value
|
$148,677,215 |
|
|
Total
Shares |
1,635,005 |
|
|
Total
Value |
$205,294,058 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
0
|
2
|
Stock
price went up :
|
0
|
2
|
Stock
price went down : |
0
|
0
|
|
|
|
Gain/Loss Ratio : |
0.0
|
2.0
|
Percentage
Gain/Loss : |
0.0%
|
14.8%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Incyte Corp |
INCY |
Director |
2020-05-26 |
256,813 |
2020-05-26 |
15,000 |
Premium* |
|
Bausch & Lomb, Inc. |
BOL.04 |
Director |
2007-10-26 |
0 |
2004-06-01 |
0 |
Premium* |
|
Verastem, Inc. |
VSTM |
Director |
2014-12-24 |
3,000 |
2014-12-24 |
0 |
Premium* |
|
Madrigal Pharmaceuticals Inc |
MDGL |
|
2024-04-08 |
185,735 |
2024-04-08 |
655,540 |
Premium* |
|
Dare Bioscience Inc |
DARE |
Director |
2017-04-03 |
18,819 |
2016-10-03 |
0 |
Premium* |
|
Alexion Pharmaceuticals Inc |
ALXN |
Director |
2021-07-21 |
0 |
2017-11-29 |
0 |
Premium* |
|
Prelude Therapeutics Inc |
PRLD |
Director |
2020-09-29 |
500,098 |
|
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
97 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 4 of 4
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
INCY |
Incyte Corp |
Director |
|
2015-02-13 |
4 |
S |
$74.25 |
$8,918,400 |
D/D |
(120,000) |
297,518 |
0 |
- |
|
BOL.04 |
Bausch & Lomb, Inc. |
Director |
|
2005-08-23 |
4 |
B |
$78.85 |
$49,676 |
D/D |
630 |
1,510 |
2.39 |
- |
|
INCY |
Incyte Corp |
Director |
|
2019-08-06 |
4 |
S |
$82.20 |
$6,406,175 |
D/D |
(77,934) |
255,531 |
0 |
- |
|
INCY |
Incyte Corp |
Director |
|
2019-08-02 |
4 |
S |
$84.41 |
$1,862,591 |
D/D |
(22,066) |
255,531 |
0 |
- |
|
INCY |
Incyte Corp |
Director |
|
2017-11-16 |
4 |
S |
$105.24 |
$3,000,077 |
D/D |
(28,507) |
269,011 |
0 |
- |
|
INCY |
Incyte Corp |
Director |
|
2015-05-26 |
4 |
S |
$107.00 |
$13,661,652 |
D/D |
(127,619) |
297,518 |
0 |
- |
|
INCY |
Incyte Corp |
Director |
|
2015-05-27 |
4 |
S |
$107.19 |
$7,435,026 |
D/D |
(69,132) |
297,518 |
0 |
- |
|
INCY |
Incyte Corp |
Director |
|
2015-05-22 |
4 |
S |
$107.75 |
$8,599,179 |
D/D |
(79,592) |
297,518 |
0 |
- |
|
INCY |
Incyte Corp |
Director |
|
2015-05-21 |
4 |
S |
$108.75 |
$2,465,742 |
D/D |
(22,651) |
297,518 |
0 |
- |
|
INCY |
Incyte Corp |
Director |
|
2015-11-17 |
4 |
S |
$111.37 |
$11,196,269 |
D/D |
(100,000) |
297,518 |
0 |
- |
|
INCY |
Incyte Corp |
Director |
|
2015-11-18 |
4 |
S |
$115.12 |
$14,415,840 |
D/D |
(125,000) |
297,518 |
0 |
- |
|
MDGL |
Madrigal Pharmaceuticals ... |
Chief Executive Officer |
|
2018-11-20 |
4 |
B |
$117.88 |
$471,520 |
D/D |
4,000 |
161,128 |
2.81 |
- |
|
INCY |
Incyte Corp |
Director |
|
2017-02-23 |
4 |
S |
$120.32 |
$6,016,000 |
D/D |
(50,000) |
297,518 |
0 |
- |
|
MDGL |
Madrigal Pharmaceuticals ... |
Chief Executive Officer |
|
2018-11-19 |
4 |
B |
$124.00 |
$496,000 |
D/D |
4,000 |
157,128 |
2.81 |
- |
|
INCY |
Incyte Corp |
Director |
|
2017-03-17 |
4 |
S |
$148.18 |
$6,178,069 |
D/D |
(41,693) |
297,518 |
0 |
- |
|
INCY |
Incyte Corp |
Director |
|
2017-03-16 |
4 |
S |
$151.45 |
$1,258,095 |
D/D |
(8,307) |
297,518 |
0 |
- |
|
MDGL |
Madrigal Pharmaceuticals ... |
Director |
|
2024-04-05 |
4 |
AS |
$240.10 |
$6,721,081 |
D/D |
(27,613) |
185,735 |
0 |
% |
|
MDGL |
Madrigal Pharmaceuticals ... |
Director |
|
2024-04-04 |
4 |
AS |
$241.07 |
$4,545,721 |
D/D |
(18,710) |
185,735 |
0 |
% |
|
MDGL |
Madrigal Pharmaceuticals ... |
Director |
|
2024-04-03 |
4 |
AS |
$242.00 |
$6,718,002 |
D/D |
(27,407) |
185,735 |
0 |
% |
|
MDGL |
Madrigal Pharmaceuticals ... |
|
|
2024-04-08 |
4 |
AS |
$242.95 |
$6,467,491 |
D/D |
(26,270) |
185,735 |
0 |
% |
|
MDGL |
Madrigal Pharmaceuticals ... |
|
|
2023-01-16 |
4 |
D |
$243.92 |
$549,796 |
D/D |
(2,254) |
20,001 |
0 |
- |
|
MDGL |
Madrigal Pharmaceuticals ... |
Chief Executive Officer |
|
2018-06-11 |
4 |
S |
$287.46 |
$21,135,784 |
I/I |
(73,526) |
655,540 |
0 |
- |
|
97 Records found
|
|
Page 4 of 4 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|